As highlighted in [Article 1] , the Indian pharmaceutical market is barreling toward a March 2026 patent cliff
This work was supported by the Shandong Province Key R&D Program (Major Science and Technology Innovation Project, 2021CXGC010509), Key Laboratory of Chronic Deficiency Liver Disease of the State Administration of Traditional Chinese Medicine of the Peoples Republic of China (20DZ2272200), Shanghai Key Specialty of Traditional Chinese Clinical Medicine (shslczdzk01201)
fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss Wilding JPH, Batterham RL, Calanna S, et al
Retatrutide is a relatively large molecule, and aggressive reconstitution can denature portions of it, reducing potency
Headache May occur during dose titration